Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $993,313.10 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 41,302 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $24.05, for a total value of $993,313.10. Following the sale, the insider owned 856,386 shares in the company, valued at $20,596,083.30. The trade was a 4.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.97 on Monday, hitting $25.03. 1,373,161 shares of the stock were exchanged, compared to its average volume of 2,697,186. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $29.98. The firm has a market capitalization of $1.49 billion, a P/E ratio of -13.60 and a beta of 0.41. The stock has a fifty day moving average price of $19.07 and a two-hundred day moving average price of $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP raised its holdings in shares of Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after purchasing an additional 910,000 shares in the last quarter. TCG Crossover Management LLC purchased a new position in Enliven Therapeutics during the second quarter valued at approximately $9,990,000. Duquesne Family Office LLC increased its holdings in Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after buying an additional 484,405 shares during the period. Candriam S.C.A. bought a new position in Enliven Therapeutics in the second quarter worth approximately $8,358,000. Finally, Franklin Resources Inc. lifted its holdings in Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after buying an additional 410,034 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.